

COVID-19 pre-exposure prophylaxis in adults



SARS-CoV-2 causes mild respiratory symptoms in most cases but can progress to severe illness leading to ARDS and multi-organ failure. **Vaccination against the virus remains the most effective way to prevent severe infection**; however severely immune-compromised individuals who are unable to mount an appropriate immune response to vaccination may develop severe infection. In such patients, **pre-exposure** prophylaxis with neutralizing antibody preparations targeting SARS-COV2 may be indicated.

The only product currently approved by Health Canada for pre-exposure prophylaxis is **Tixagevimab/Cilgavimab (Evusheld)**. This product is **not a substitute for vaccination; should not be given as treatment for active infection nor as post-exposure prophylaxis**. The management of actively infected patients (testing positive for SARS-CoV2) is described under “COVID-19 Management guidelines – suspected and confirmed COVID-19”.

WHO SHOULD RECEIVE PRE-EXPOSURE PROPHYLAXIS?

Individuals with **NO symptoms** of COVID-19 (fever and/or new/exacerbation of respiratory symptoms and/or new onset of diarrhea) and not known positive for SARS-CoV2 (by PCR or rapid antigen test within last 2 weeks). While supplies are limited, **priority should be given to highest-risk individuals (listed in Box 1)**

HIGHEST PRIORITY, irrespective of vaccination status:

- Solid organ recipient (kidney, liver, heart, lungs), or
- Recipient of Allo or Auto-SCT within <1 year, or on treatment for CGVHD
- Recipient of CAR-T therapy within <1 year, or
- Hematologic malignancy on chemotherapy and/or immunotherapy, or
- Severe primary immunodeficiency (CVID, DiGeorge, Wiskott-Aldrich, HyperIgE), hypogammaglobulinemia,
- Receiving B-cell depleting agent (ex. Rituximab) for any condition, or
- Receiving cyclophosphamide for any condition, or
- Receiving > 20mg/d Prednisone for > 3 weeks

Unvaccinated or incompletely vaccinated (≤ 2 doses of mRNA vaccines) AND contra-indication to further vaccination (eg. Severe adverse events to vaccination) AND

- Active solid organ malignancy (undergoing chemotherapy /radiotherapy/immunotherapy)
- Serious cardiovascular disease (unstable CAD, uncontrolled CHF (NYHA II-IV), severe arrhythmia)
- Severe lung disease (severe asthma, COPD, CF, pulmonary fibrosis)
- Chronic kidney disease on dialysis
- Chronic liver disease
- Sickle cell disease
- Poorly controlled Diabetes, Obesity (BMI ≥35)
- Down Syndrome (trisomy 21)
- HIV infection with CD4<200
- Age > 60y

ADMINISTRATION:

Tixagevimab/cilgavimab¹: tixagevimab 150 mg (1.5 mL) AND cilgavimab 150 mg (1.5 mL) IM as 2 distinct IM injection sites, preferably the two gluteal² muscles
Should be administered at least 2 weeks after COVID vaccination³
Dose may be repeated in 6 months if ongoing community transmission of SARS-CoV2.



Antimicrobial
Stewardship
Program

Centre universitaire
de santé McGill



McGill University
Health Centre

ADDITIONAL NOTES

¹Tixagevimab/cilgavimab (T/C):

- Active vs $\alpha, \beta, \lambda, \gamma, \delta$ including BA2 variant (but less active vs BA1 variant);
- Dose may be increased depending on predominant variant (eg. BA1); Viral evolution will affect T/C efficacy; optimal dosing not well established.
- Caution is recommended in patients with history of significant cardiovascular disease.
- Insufficient data to recommend use in pregnant women
- Potential adverse events include injection site reactions and hypersensitivity reactions
- Not expected to interact with any drugs, and is not renally excreted or metabolized by cytochrome P450

² **Injection site** : if the gluteal muscles are not available, another large muscle capable of accepting the injection volume, such as the vastus lateralis, would be acceptable.

³ **Timing in relation to COVID vaccination**: T/C should be administered at least 2 weeks after COVID vaccination, but optimal delay between vaccination and T/C is still not well documented

REFERENCES

- INESSS. COVID-19 et Immunoprophylaxie par anticorps neutralisant le SRAS-CoV-2. [Online] Consulted 05May2022. Available: https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/Covid-19_Prophylaxie_Ac_neutralisant_VF.pdf
- NIH. COVID-19 Treatment guidelines. [Online] Consulted 05May2022. Available: <https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf>
- IDSA. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. [Online] Consulted 05May2022. Available: <https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v8.0.0.pdf>
- AstraZeneca. Product Monograph: Evusheld. [Online] Consulted 05May2022. Available: <https://covid-vaccine.canada.ca/info/pdf/evusheld-pm-en.pdf>
- Levin MJ et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2021 Mar 11;384(10):905-914.

Drafted by F.Bourdeau (pharmacy) and M. Semret (ID)

Reviewed by Don Vinh, Matt Cheng, Marina Klein, Todd Lee, Jesse Papenburg, Marcel Behr (ID), C. Dupont, Nancy Sheehan (Pharm)

Approved by ASP committee and **MUHC P&T committee on 20220518**